Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer

Documenti analoghi

• Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies
  di: Tinhofer, Ingeborg, et al.
  Pubblicazione: (2020)
• Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix
  di: Rieke, Damian T., et al.
  Pubblicazione: (2016)
• Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts
  di: Yao, Wenhao, et al.
  Pubblicazione: (2021)
• The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer
  di: Tinhofer, Ingeborg, et al.
  Pubblicazione: (2016)
• Mutational load and mutational patterns in relation to age in head and neck cancer
  di: Meucci, Stefano, et al.
  Pubblicazione: (2016)